论文部分内容阅读
在糖尿病微血管病变的未来治疗议题上,美国糖尿病协会第63界科学会议期间选择了眼睛作为研究模型。而别的靶位如肾脏和神经,在上个世纪80～90年代期间,已有很多卓有成效的试验和临床研究。伴随着糖尿病控制和并发症试验(DCCT)以及英国糖尿病前瞻性研究(UKPDS),目前糖尿病性视网膜病变成了临床研究的重点。上述两个研究均表明控制好血糖能阻止糖尿病性视网膜病变的发生(1型)和发展(1型和2型),因此,糖尿病患者应尽可能控制好血糖。然而,应注意到还有大量的糖尿病患者没有控制好血糖。在美国,平均糖化血红蛋白(HbA1c)超过8％,而要防止并发症则需低于7％。
In the future treatment of diabetic microangiopathy topics, the American Diabetes Association 63th Science Conference selected the eyes as a research model. Other targets, such as the kidneys and nerves, have had many successful trials and clinical studies during the 1980s and 1990s. With the Diabetes Control and Complications Trial (DCCT) and the UK Prospective Diabetes Study (UKPDS), diabetic retinopathy is currently the focus of clinical research. Both studies show that controlling good blood glucose can prevent the development of diabetic retinopathy (type 1) and development (type 1 and type 2), so people with diabetes should control their blood sugar as much as possible. However, it should be noted that a large number of people with diabetes do not control their blood sugar. In the United States, mean HbA1c levels exceed 8%, while complications need to be less than 7%.